Why a treatment history beats a rewritten first-visit guide
A patient who has already had treatment for non-small cell lung cancer is not starting from zero. The China team needs to know what was given, when, why it stopped and what happened next. That is a different document from a general first-visit guide, which spends space on symptoms, travel and background.
The practical reason is that NSCLC decisions depend on prior exposure. A clinician reviewing a confirmed or suspected case needs to see whether the disease progressed during or after a treatment, whether it responded, and whether toxicity limited further use. A chronological treatment table answers those questions faster than a long narrative.
Consider what a first-visit guide contains. It explains the diagnosis, lists symptoms, describes the hospital and gives travel advice. None of that tells a reviewer what has already been tried. A patient who has completed two lines of systemic therapy and chest radiotherapy needs a different document from someone who has just received a diagnosis.
The distinction matters because prior therapy narrows and reshapes the remaining options. A drug that has already failed is unlikely to be repeated without a specific reason. A site that has already received a full course of radiation may not tolerate another course at the same dose. A tumour that shrank on a targeted agent but later grew may need new testing to understand why.
A treatment history also prevents wasted effort. If the summary is unclear, the reviewer may ask for records that already exist, or may form an incomplete picture of how the disease has behaved. A clear chronological table lets the clinical team spend its time on the actual question rather than on reconstructing the past.
This article is about preparing that summary for care in China. It is not a treatment recommendation, and it does not replace the treating team's assessment. The hospital decides suitability after reviewing the records. The aim is to give the reviewer enough to judge whether the records are sufficient for a review, and what else they need.
Write the summary as if the reader has five minutes. Put the diagnosis, stage and biomarker results at the top. Then list each treatment line in order. Then state the current question. Supporting reports follow behind the summary, not in front of it.
One more distinction: a treatment history is not a request for a new plan. It is a factual record of what happened. The China team can then decide whether the records support a review, whether more information is needed, and whether any tests should be repeated. That sequence keeps the enquiry honest and the reviewer focused.
What to include in the previous-therapy summary
Write one line per treatment episode. For each line, state the start and stop dates, the treatment type, the reason it stopped, the best response recorded and any significant toxicity. If a treatment is ongoing, say so and give the current cycle or date.
For systemic therapy, name the regimen rather than writing 'chemotherapy'. If targeted therapy or immunotherapy was used, name the agent and the biomarker that supported it. For radiotherapy, give the site, technique if known, and total dose if available. For surgery, give the procedure and the date.
For a lung lobectomy, the operation removes one lobe of the lung; it is different from removal of an entire lung. That distinction matters when a later clinician is judging what lung function and anatomy remain. Ask the treating team how they want prior surgery described if the operative note is unavailable.
Add a short 'current question' at the top. Examples: whether a new systemic option is reasonable after progression on a named therapy, or whether local treatment of a specific site should be considered. A clear question helps the reviewer focus.
- One line per treatment: dates, type, reason stopped, response, toxicity.
- Pathology report with NSCLC subtype and stage at diagnosis.
- Biomarker reports: EGFR, ALK, ROS1, BRAF, KRAS, PD-L1 and any others already tested.
- Imaging reports and the actual images, not only the written report.
- Operative notes and radiotherapy summaries, if available.
- Current medication list, including supportive care and anticoagulants.
- The single question you want the China team to answer.
Pathology and biomarker reports: what the reviewer needs to see
Pathology and biomarker reports are the backbone of an NSCLC review. The original pathology report should state the subtype and the stage at diagnosis. If a later biopsy was taken after progression, include that report too, because the disease may have changed.
Biomarker testing is not a single test. It can include EGFR, ALK, ROS1, BRAF, KRAS, PD-L1 and others. For each result, give the test method, the date and the laboratory. If a test was attempted but failed because of insufficient tissue, say that, because it changes what the next step might be.
If no biomarker testing has been done, do not assume it will be ordered in China. Ask the receiving team whether repeat testing is needed and whether a new biopsy or a blood-based test is appropriate. That is a clinical decision for them.
Keep the reports in their original language and add a short English summary. Do not translate a pathology report yourself if you are not qualified; a mistranslated biomarker result can mislead the review.
Local and systemic options: how prior therapy changes the question
Local options and systemic options are not competing categories. They answer different questions. Local treatment targets a specific site, such as a lung tumour or a metastasis. Systemic treatment affects the whole body.
Previous therapy changes which local and systemic options remain plausible. If a patient has already received a targeted therapy and progressed, the next systemic choice may depend on the resistance mechanism, which may require new testing. If a patient has had chest radiotherapy, further radiation to the same area may be limited by prior dose.
This is why the summary should not simply list drug names. It should state what happened after each treatment. A reviewer who sees 'carboplatin plus pemetrexed, stopped after four cycles, progression on scan' has a different picture from one who sees 'chemotherapy, completed'.
Do not ask the China team to recommend a regimen from a summary alone. Ask whether the records are sufficient for a review, and what additional information they need.
A practical way to organise the file
Use a single PDF or folder with a one-page cover summary, then the supporting reports in date order. The cover summary should be no longer than one page. It should contain the diagnosis, stage, biomarker results, treatment lines and the current question.
Label each file clearly: '2023-04 CT chest report', '2023-05 pathology', '2023-06 EGFR result'. Avoid file names like 'scan1' or 'report final'. The reviewer should be able to find a document without opening every file.
If records are missing, say so in the cover summary. Do not fill gaps with guesses. A reviewer who knows a report is missing can ask for it; a reviewer who assumes a test was normal may make a different judgement.
For an initial enquiry, a short summary is enough. The full archive can follow after first contact. Do not send passport numbers, payment details or a complete medical archive through the first enquiry form.
What to confirm with the China team before you travel
Before arranging travel, confirm what the hospital needs and what it can do remotely. Ask whether the records are sufficient for a specialist review, whether a proxy consultation is needed, and whether any tests must be repeated in China.
Ask how the hospital wants prior therapy documented if the original records are incomplete. Ask whether the review is a records-based opinion or a confirmed appointment, because those are different stages. A records-based opinion does not establish hospital acceptance or final eligibility.
Ask what the written estimate or treatment plan will include, and which charges are paid to the hospital rather than to a coordination service. Do not assume that a foreign hospital's ward routine applies in China; ask the named provider about its own arrangements.
If symptoms are worsening or urgent, seek local care first. An overseas enquiry should not delay necessary assessment.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.